By Adam Whittaker

AstraZeneca is scheduled to report results for the second quarter on Tuesday. Here is what you need to know.

CORE EARNINGS PER SHARE: Core earnings per share--one of the British pharmaceutical major's preferred metrics--are expected to be $2.16, according to company-compiled consensus based on 15 analysts' estimates. This compares with $1.98 it reported in the same period a year prior.

REVENUE: Total revenue is expected at $14.15 billion, according to the company-compiled consensus. For the same period in the year prior, it reported total revenue of $12.94 billion.

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

--EARNINGS: AstraZeneca's earnings are expected to be in line with the company-compiled consensus, Barclays analysts write. Its results will demonstrate its resilience despite changes to Medicare, and headwinds for its anti-blood clot medication Brilinta in the U.S. and Europe, they added. Meanwhile, the company will benefit from a weaker U.S. dollar versus the pound and euro, which will likely drive earnings momentum into the second half and 2026, UBS analysts wrote.

--U.S INVESTMENT: Market watchers will be looking for more information about AstraZeneca's plans to invest $50 billion in the U.S. by 2030. Announced on Monday, the investment will include a manufacturing facility in Virginia which will be its largest single investment in a facility to date.

--KEY DRUGS: Investor focus will be on U.S. oral oncology volumes, Brilinta erosion trends following generic issuance in the U.S. and Europe, as well updates on its Farxiga drug and its oncology drug Lynparza.

--CHINA: Investors will be looking for commentary from AstraZeneca on operations in China and on the anti-corruption investigation into some of its employees taking place in the country. At the moment, China "remains well under control with no material new developments on ongoing legal processes," Barclays analysts wrote.

Write to Adam Whittaker at adam.whittaker@wsj.com

(END) Dow Jones Newswires

July 25, 2025 09:00 ET (13:00 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.